The transformation of Medivir

For more than a year or so, we have worked very determinedly with the transformation of Medivir into a new, exciting biotech company, with a clear focus on our prioritised projects and the aim to improve life for patients through transformative drugs.

A lot of work has been spent on our science and the continued development of our broad pipeline – including both potential blockbusters and orphan drugs - and strong discovery engine. But we have also fine-tuned and redeveloped other parts and aspects of the company, in order to better present our strengths and capabilities. This refurbishment process includes of course also our communication with investors, journalists and other stakeholders. One such special project is the new company website, which I am proud and happy to announce the launch of today.

Not only have we given it a totally new, modern look, but we have also tried to make it as informative and interesting as possible. We will ensure that it is fresh and updated, with relevant information about the company, our projects and also the areas which we are focused on, not the least oncology. Please feel free to come back to us with feedback so that we can improve further.

Also, to strengthen our contacts with our stakeholders, we will this year initiate a quarterly newsletter, with related interviews, reports from investor and scientific conferences, in-depth descriptions of our pipeline and other news. Please stay tuned for these exciting happenings.

In the meantime, I hope you enjoy the new website. And again: feel free to come back to us if you have ideas for further improvement.